UBT251 is a long-acting synthetic triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, jointly developed by United Biotechnology and Novo Nordisk. Phase 2 data in Chinese patients with type 2 diabetes showed significant HbA1c and weight reductions, and global phase 1b/2a and phase 2 programs are ongoing. It remains investigational and not yet approved.
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Novo Nordisk and China's United Biotechnology reported that experimental obesity drug UBT251 led to mean weight loss of up to 19.7% in a midstage clinical trial in China, expanding Novo's obesity pipeline.
Novo Nordisk's experimental triple-action obesity drug UBT251 achieved up to 19.7% weight loss in a Phase 2 trial in China, as the company works to regain ground against rival Eli Lilly in the obesity drug market.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07395687 |
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity |
RECRUITING | PHASE2 |
| NCT07145151 |
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
RECRUITING | PHASE2 |
| NCT07134335 |
UBT251 Injection Phase II Clinical Study (CKD) |
RECRUITING | PHASE2 |
